Genetic analysis of pediatric primary adrenal insufficiency of unknown etiology: 25 years’ experience in the UK


1UCL GOS Institute of Child Health, London, UK; 2Queen Mary University of London, London, UK; 3Technische Universität Dresden, Dresden, Germany; 4Barts Health NHS Trust, London, UK; 5University Hospital Southampton NHS Foundation Trust, Southampton, UK; 6King’s College Hospital NHS Foundation Trust, London, UK; 7Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK; 8University Hospitals Bristol and Bath, Bristol, UK; 9University of Southampton, Southampton, UK; 10Cardiff University, Cardiff, UK; 11University College London Hospitals, London, UK; 12Guy’s and St Thomas’ NHS Trust, London, UK; 13Sheffield Children’s Hospital, Sheffield, UK; 14Royal Hospital for Children, NHS Greater Glasgow and Clyde, Glasgow, UK; 15International Centre for Life, Newcastle, UK; 16Manchester University NHS Foundation Trust, Manchester, UK; 17Salisbury District Hospital, Salisbury, UK. Last two authors contributed equally.

Introduction

• Primary adrenal insufficiency (PAI) is a potentially life-threatening condition that requires appropriate diagnosis and treatment
• The most common cause of PAI is congenital adrenal hyperplasia (CAH), but other well-established aetiologies include metabolic and autoimmune disorders, and physical damage
• In addition, pathogenic variants in more than 30 genes have now been associated with PAI, with considerable biochemical and phenotypic overlap. It is therefore important to adopt comprehensive genetic analysis to help reach a diagnosis

Aim

• We report the molecular basis underlying PAI in children and young people over a 25 year-period, combining published and unpublished data from our research centres

Methods

Patient cohort

• 155 children with PAI of unknown aetiology from the UK studied at three research centres from 1993 until 2018
• Children with CAH, metabolic and autoimmune causes of PAI were excluded
• An additional sub-group of 51 patients were included where a genetic diagnosis of X-linked adrenal hypoplasia congenita (AHC) due to pathogenic variants in NR0B1 (DAX-1) had been established through clinical genetic testing services

Genetic analysis

• Sanger sequencing and a candidate gene approach (1993 onwards) or next generation sequencing (NGS), using both targeted panels and whole exome sequencing (WES) (2013-2018)

Results

• An excess of boys was observed, even when individuals with X-linked AHC were excluded from analysis
• This difference in sex ratio was even more marked in the "undiagnosed" group of patients

Conclusions

• Although age at presentation, treatment, and other factors such as ancestral background and birthweight can provide diagnostic clues, genetic testing was required to establish the definitive cause
• NGS approaches improve the diagnostic yield when many potential candidate genes are involved
• Defining the specific aetiology has important implications for affected individuals and their families for the management of this lifelong condition:
  • monitoring associated features
  • counselling about recurrence risk in families
  • predicting disease course and modifying treatment

© The Authors

[Diagram: Genetic analysis of pediatric primary adrenal insufficiency of unknown etiology: 25 years’ experience in the UK]